Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Apellis Pharmaceuticals Inc (APLS)  
$42.75 1.05 (2.52%) as of 4:30 Tue 6/11


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 114,470,000
Market Cap: 4.89(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $23.65 - $93.31
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutic compounds to treat disease through the inhibition of the complement system at the level of C3. Co.'s primary product candidate, pegcetacoplan, is a conjugate of a compstatin analogue, formulated both for intravitreal administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin. Co. is also developing APL-9 for the prevention of complement immune system activation coincident with adeno-associated virus vector administration for gene therapies and other indications.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 180,792 624,919 926,129 1,524,597
Total Sell Value $8,962,693 $37,328,501 $54,378,139 $94,079,798
Total People Sold 5 12 14 16
Total Sell Transactions 6 55 79 155
End Date 2024-03-14 2023-12-12 2023-06-13 2022-06-13

   
Records found: 714
  Page 16 of 29  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Delong Mark Jeffrey Senior Vice President   •       •      –    2022-04-20 4 OE $15.52 $108,640 D/D 7,000 35,481     -
   Machiels Alec Director   •       •      –    2022-04-14 4 AS $50.90 $63,625 D/D (1,250) 263,774 12%     
   Machiels Alec Director   •       •      –    2022-04-14 4 OE $2.67 $3,338 D/D 1,250 265,024     -
   Scheibler Lukas CHIEF INNOVATION OFFICER   •       •      –    2022-04-05 4 AS $60.09 $36,593 D/D (609) 52,233 16%     
   Scheibler Lukas CHIEF INNOVATION OFFICER   •       •      –    2022-04-05 4 OE $13.85 $8,435 D/D 609 52,842     -
   Scheibler Lukas CHIEF INNOVATION OFFICER   •       •      –    2022-04-04 4 AS $55.84 $199,589 D/D (3,504) 52,233 16%     
   Scheibler Lukas CHIEF INNOVATION OFFICER   •       •      –    2022-04-04 4 OE $13.85 $48,530 D/D 3,504 55,737     -
   Scheibler Lukas CHIEF INNOVATION OFFICER   •       •      –    2022-04-01 4 AS $55.05 $632,855 D/D (11,496) 52,233 19%     
   Scheibler Lukas CHIEF INNOVATION OFFICER   •       •      –    2022-04-01 4 OE $13.85 $159,220 D/D 11,496 63,729     -
   Brown Victoria L. Program Team Lead   •       •      –    2022-03-25 4 D $49.28 $4,041 D/D (82) 28,325     -
   Machiels Alec Director   –       •      –    2022-03-15 4 AS $39.57 $49,463 D/D (1,250) 259,544 36%     
   Machiels Alec Director   –       •      –    2022-03-15 4 OE $2.67 $3,338 D/D 1,250 260,794     -
   Grossi Federico CHIEF MEDICAL OFFICER   •       •      –    2022-03-15 4 AS $39.57 $14,839 D/D (375) 116,436 36%     
   Grossi Federico CHIEF MEDICAL OFFICER   •       •      –    2022-03-15 4 OE $4.31 $30,170 D/D 7,000 116,811     -
   Grossi Federico CHIEF MEDICAL OFFICER   •       •      –    2022-03-01 4 AS $43.53 $16,324 D/D (375) 109,811 4%     
   Grossi Federico CHIEF MEDICAL OFFICER   •       •      –    2022-02-23 4 OE $4.31 $17,671 D/D 4,100 110,186     -
   Machiels Alec Director   •       •      –    2022-02-15 4 AS $45.43 $56,788 D/D (1,250) 673,774 -1%     
   Machiels Alec Director   •       •      –    2022-02-15 4 OE $2.67 $3,338 D/D 1,250 675,024     -
   Grossi Federico CHIEF MEDICAL OFFICER   •       •      –    2022-02-15 4 AS $45.43 $17,036 D/D (375) 106,086 -1%     
   Scheibler Lukas CHIEF INNOVATION OFFICER   •       •      –    2022-02-14 4 OE $26.73 $19,246 D/D 720 52,233     -
   Grossi Federico CHIEF MEDICAL OFFICER   •       •      –    2022-02-14 4 OE $4.31 $15,516 D/D 3,600 106,461     -
   Scheibler Lukas CHIEF INNOVATION OFFICER   •       •      –    2022-02-11 4 AS $46.80 $77,969 D/D (1,666) 51,513 2%     
   Sullivan Timothy Eugene Chief Financial Officer   •       •      –    2022-02-10 4 D $47.12 $41,230 D/D (875) 103,403     -
   Grossi Federico CHIEF MEDICAL OFFICER   •       •      –    2022-02-10 4 D $47.12 $33,220 D/D (705) 102,861     -
   Townsend Adam J. Chief Commercial Officer   •       •      –    2022-02-10 4 D $47.12 $42,172 D/D (895) 44,013     -

  714 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 16 of 29
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed